Purpose/Background: The aim of this study was to report a patient with vitreoretinal lymphoma with clinical features providing hypothesis-generating insights into the pathophysiology of this disease. Methods: Clinical history and imaging studies (i.e., fundus photography, optical coherence tomography, fundus autofluorescence, and fluorescein angiography) were documented. Results: A 71-year-old woman presented with a 2-month history of blurred vision in the right eye and bilateral vitreous infiltrates unresponsive to topical and systemic steroids. Vitreous biopsy of the left eye was diagnostic for lymphoma. Bulky subretinal deposits in the right eye responded to systemic therapy. The left fundus showed diffuse hypoautofluorescence and punctate, hyperfluorescent sub-retinal pigment epithelial tumor deposits, which resolved leaving hypoautofluorescent atrophic retinal pigment epithelium (RPE) scars, except inferotemporally, where retinal vasculopathy had occurred. Conclusions: The clinical features suggest that occlusion of the inferotemporal retinal arteriole prevented sub-RPE lymphomatous deposits and subsequent RPE atrophy in this area of vascular nonperfusion. This suggests that “primary” vitreoretinal lymphoma is secondary to hematogenous spread from systemic loci. This finding, together with the ocular tumor control achieved entirely by systemic therapy, indicates scope for studies investigating systemic treatment protocols, especially those including immune-modulatory agents.

Keywords:
Lymphoma, Retinal disease
1.
Araujo I, Coupland SE: Primary vitreoretinal lymphoma – a review. Asia Pac J Ophthalmol 2017; 6: 283–289.
2.
Reichstein D: Primary vitreoretinal lymphoma: an update on pathogenesis, diagnosis and treatment. Curr Opin Ophthalmol 2016; 27: 177–184.
3.
Witmer MT: Primary vitreoretinal lymphoma: management of isolated ocular disease. Cancer Control 2016; 23: 110–116.
4.
Teckie S, Yahalom J: Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone. Leuk Lymphoma 2014; 55: 795–801.
5.
Frenkel S, Hendler K, Siegal T, Shalom E, Pe’er J: Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 2008; 92: 383–388.
6.
Riemens A, Bromberg J, Touitou V, Sobolewska B, Missotten T, Baarsma S, Hoyng C, Cordero-Coma M, Tomkins-Netzer O, Rozalski A, Tugal-Tutkun I, Guex-Crosier Y, Los LI, Bollemeijer JG, Nolan A, Pawade J, Willermain F, Bodaghi B, ten Dam-van Loon N, Dick A, Zierhut M, Lightman S, Mackensen F, Moulin A, Erckens R, Wensing B, Ie Hoang P, Lokhorst H, Rothova A: Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative. JAMA Ophthalmol 2015; 133: 191–197.
7.
Carnevale J, Rubenstein JL: The challenge of primary central nervous system lymphoma. Hematol Oncol Clin North Am 2016; 30: 1293–1316.
8.
McCann KJ, Ashton-Key M, Smith K, Stevenson FK, Ottensmeier CH: Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. Blood 2009; 113: 4677–4680.
9.
Rubenstein JL, Treseler PA, Stewart PJ: Regression of intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol 2011; 29:e595–e597.
10.
Bever GJ, Kim DJ, Afshar AR, Rubenstein JL, Damato BE: Therapeutic vitrectomy as an adjunct treatment to systemic chemotherapy for intraocular lymphoma. Retin Cases Brief Rep 2017, DOI: 10.1097/ICB.0000000000000668.
11.
Venkatesh P, Gogia V, Khanduja S, Gupta S, Kumar L, Garg S: Therapeutic vitrectomy for vitreal recurrence of intraocular lymphoma resistant to intravitreal methotrexate post systemic chemotherapy. J Cancer Res Ther 2015; 11: 668.
12.
Pakdel A, Mammo Z, Hollands H, Forooghian F: Regression of subretinal lymphoma after diagnostic vitrectomy. JAMA Ophthalmol 2017; 135: 503–505.
13.
Shields CL, Sioufi K, Mashayekhi A, Shields JA: Intravitreal melphalan for treatment of primary vitreoretinal lymphoma: a new indication for an old drug. JAMA Ophthalmol 2017; 135: 815–818.
14.
Coupland SE, Damato B: Understanding intraocular lymphomas. Clin Exp Ophthalmol 2008; 36: 564–578.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.